Event Brief
Mar 25, 2026 at 2:03 AM ET
Research team confirms safety of Alzheimer's drug Lecanemab
By The BriefBrief
A study shows over 90% of patients in Japan can continue Lecanemab treatment without severe side effects.
WHO: Research team
WHAT: Confirmed safety of Alzheimer's drug Lecanemab
WHEN: Mar 25, 2026 at 1:39 AM ET
WHERE: Japan
WHY: To assess the health status of patients after treatment with Lecanemab.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Page 21450 of 21449
Same format. Every time.
Continue reading — sign in or create a free account with
